ESCO2 Inhibitors

ESCO2 inhibitors, as considered here, primarily target pathways and processes associated with DNA replication, damage response, and cell cycle regulation. Compounds such as Aphidicolin, Hydroxyurea, and Camptothecin disrupt DNA replication either by directly inhibiting replication enzymes or by inducing DNA damage. This interference can indirectly impede ESCO2's role in establishing sister chromatid cohesion during the S phase. In a similar vein, Mitomycin C creates DNA crosslinks, adding another layer of complexity to the replication machinery.

Furthermore, inhibitors like AZD7762, ATR inhibitor VE-821, and ATM inhibitor KU-55933 focus on cell cycle checkpoints and DNA damage responses. These compounds modulate the cellular response to DNA damage and replication stress, indirectly influencing processes where ESCO2 plays a role. Additionally, inhibitors such as the WEE1 inhibitor MK-1775, Olaparib, and the RAD51 inhibitor B02 target different facets of DNA repair mechanisms, further adding to the intricate network of processes related to sister chromatid cohesion. Palbociclib, a CDK4/6 inhibitor, and Gemcitabine, a nucleoside analog, provide insights into how cell cycle progression and DNA synthesis can be targeted to indirectly modulate ESCO2-associated pathways.